{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T11:14:33Z","timestamp":1794482073626,"version":"4.9.1"},"reference-count":45,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"6","license":[{"start":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T00:00:00Z","timestamp":1675296000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Tyrosine kinase inhibitor therapy revolutionized chronic myeloid leukemia treatment and showed how targeted therapy and molecular monitoring could be used to substantially improve survival outcomes. We used chronic myeloid leukemia as a model to understand a critical question: why do some patients have an excellent response to therapy, while others have a poor response? We studied gene expression in whole blood samples from 112 patients from a large phase III randomized trial (clinicaltrials gov. Identifier: NCT00471497), dichotomizing cases into good responders (BCR::ABL1 \u226410% on the International Scale by 3 and 6 months and \u22640.1% by 12 months) and poor responders (failure to meet these criteria). Predictive models based on gene expression demonstrated the best performance (area under the curve =0.76, standard deviation =0.07). All of the top 20 pathways overexpressed in good responders involved immune regulation, a finding validated in an independent data set. This study emphasizes the importance of pretreatment adaptive immune response in treatment efficacy and suggests biological pathways that can be targeted to improve response.<\/jats:p>","DOI":"10.3324\/haematol.2022.281878","type":"journal-article","created":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T03:36:09Z","timestamp":1675308969000},"page":"1567-1578","source":"Crossref","is-referenced-by-count":12,"title":["Molecular response in newly diagnosed chronic-phase chronic myeloid leukemia: prediction modeling and pathway analysis"],"prefix":"10.3324","volume":"108","author":[{"given":"Jerald P.","family":"Radich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Wall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Branford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catarina D.","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shalini","family":"Chaturvedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"DeAngelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Deininger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Guinney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Hochhaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy P","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop M.","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Larson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sai","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo","family":"Maegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaushal","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Obourn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Pinilla-Ibarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Das","family":"Purkayastha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Islam","family":"Sadek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Saglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alok","family":"Shrestha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian S.","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian J.","family":"Druker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2023,2,2]]},"reference":[{"key":"48400","doi-asserted-by":"crossref","unstructured":"Bower H, Bjorkholm M, Dickman PW, Hoglund M, Lambert PC, Andersson TM. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol. 2016; 34(24):2851-2857.","DOI":"10.1200\/JCO.2015.66.2866"},{"key":"48401","doi-asserted-by":"crossref","unstructured":"Jabbour E. Chronic myeloid leukemia: first-line drug of choice. Am J Hematol. 2016; 91(1):59-66.","DOI":"10.1002\/ajh.24249"},{"key":"48402","doi-asserted-by":"crossref","unstructured":"Saglio G, Kim DW, Issaragrisil S. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010; 362(24):2251-2259.","DOI":"10.1056\/NEJMoa0912614"},{"key":"48403","doi-asserted-by":"crossref","unstructured":"Kantarjian H, Shah NP, Hochhaus A. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010; 362(24):2260-2270.","DOI":"10.1056\/NEJMoa1002315"},{"key":"48404","doi-asserted-by":"crossref","unstructured":"Cortes JE, Saglio G, Kantarjian HM. Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naive chronic myeloid leukemia patients trial. J Clin Oncol. 2016; 34(20):2333-2340.","DOI":"10.1200\/JCO.2015.64.8899"},{"key":"48405","doi-asserted-by":"crossref","unstructured":"Hochhaus A, Saglio G, Hughes TP. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia. 2016; 30(5):1044-1054.","DOI":"10.1038\/leu.2016.5"},{"key":"48406","doi-asserted-by":"crossref","unstructured":"Kantarjian HM, Hughes TP, Larson RA. Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis. Leukemia. 2021; 35(7):2142-2143.","DOI":"10.1038\/s41375-021-01306-1"},{"key":"48407","doi-asserted-by":"crossref","unstructured":"Brummendorf TH, Cortes JE, Milojkovic D. Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial. Leukemia. 2022; 36(7):1825-1833.","DOI":"10.1038\/s41375-022-01589-y"},{"key":"48408","doi-asserted-by":"crossref","unstructured":"Marin D, Ibrahim AR, Lucas C. Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol. 2012; 30(3):232-238.","DOI":"10.1200\/JCO.2011.38.6565"},{"key":"48409","doi-asserted-by":"crossref","unstructured":"Hanfstein B, Muller MC, Hehlmann R. Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia. 2012; 26(9):2096-2102.","DOI":"10.1038\/leu.2012.85"},{"key":"48410","doi-asserted-by":"crossref","unstructured":"Neelakantan P, Gerrard G, Lucas C. Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies. Blood. 2013; 121(14):2739-2742.","DOI":"10.1182\/blood-2012-11-466037"},{"key":"48411","unstructured":"NCCN Clinical Practice Guidelines in Oncology. Chronic Myeloid Leukemia. 2021."},{"key":"48412","doi-asserted-by":"crossref","unstructured":"Hochhaus A, Baccarani M, Silver RT. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020; 34(4):966-984.","DOI":"10.1038\/s41375-020-0776-2"},{"key":"48413","doi-asserted-by":"crossref","unstructured":"Hughes TP, Saglio G, Kantarjian HM. Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib. Blood. 2014; 123(9):1353-1360.","DOI":"10.1182\/blood-2013-06-510396"},{"key":"48414","doi-asserted-by":"crossref","unstructured":"Jain P, Kantarjian H, Nazha A. Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities. Blood. 2013; 121(24):4867-4874.","DOI":"10.1182\/blood-2013-03-490128"},{"key":"48415","doi-asserted-by":"crossref","unstructured":"Jabbour E, Kantarjian HM, Saglio G. Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood. 2014; 123(4):494-500.","DOI":"10.1182\/blood-2013-06-511592"},{"key":"48416","doi-asserted-by":"crossref","unstructured":"Hochhaus A, Rosti G, Cross NC. Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study. Leukemia. 2016; 30(1):57-64.","DOI":"10.1038\/leu.2015.270"},{"key":"48417","doi-asserted-by":"crossref","unstructured":"Mahon FX, Nicolini FE, No\u00ebl MP. Preliminary report of the STIM2 study: a multicenter stop imatinib trial for chronic phase chronic myeloid leukemia de novo patients on imatinib. Blood. 2013; 122(21):654.","DOI":"10.1182\/blood.V122.21.654.654"},{"key":"48418","doi-asserted-by":"crossref","unstructured":"Mahon FX, Rea D, Guilhot J. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010; 11(11):1029-1035.","DOI":"10.1016\/S1470-2045(10)70233-3"},{"key":"48419","doi-asserted-by":"crossref","unstructured":"Ross DM, Branford S, Seymour JF. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood. 2013; 122(4):515-522.","DOI":"10.1182\/blood-2013-02-483750"},{"key":"48420","doi-asserted-by":"crossref","unstructured":"Branford S, Wang P, Yeung DT. Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease. Blood. 2018; 132(9):948-961.","DOI":"10.1182\/blood-2018-02-832253"},{"key":"48421","doi-asserted-by":"crossref","unstructured":"Becht E, Giraldo NA, Lacroix L. Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biol. 2016; 17(1):218.","DOI":"10.1186\/s13059-016-1070-5"},{"key":"48422","unstructured":"Korotkevich G, Sukhov V, Sergushichev A. Fast gene set enrichment analysis. bioRxiv. 2019. Publisher Full Text|"},{"key":"48423","doi-asserted-by":"crossref","unstructured":"Wall MA, Turkarslan S, Wu WJ. Genetic program activity delineates risk, relapse, and therapy responsiveness in multiple myeloma. NPJ Precis Oncol. 2021; 5(1):60.","DOI":"10.1038\/s41698-021-00185-0"},{"key":"48424","doi-asserted-by":"crossref","unstructured":"Naka K, Hoshii T, Muraguchi T. TGF-beta-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia. Nature. 2010; 463(7281):676-680.","DOI":"10.1038\/nature08734"},{"key":"48425","doi-asserted-by":"crossref","unstructured":"Song X, Wang S, Li L. New insights into the regulation of Axin function in canonical Wnt signaling pathway. Protein Cell. 2014; 5(3):186-193.","DOI":"10.1007\/s13238-014-0019-2"},{"key":"48426","doi-asserted-by":"crossref","unstructured":"Gerlach JP, Emmink BL, Nojima H, Kranenburg O, Maurice MM. Wnt signalling induces accumulation of phosphorylated beta-catenin in two distinct cytosolic complexes. Open Biol. 2014; 4(11):140120.","DOI":"10.1098\/rsob.140120"},{"key":"48427","doi-asserted-by":"crossref","unstructured":"Radich JP, Dai H, Mao M. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci U S A. 2006; 103(8):2794-2799.","DOI":"10.1073\/pnas.0510423103"},{"key":"48428","doi-asserted-by":"crossref","unstructured":"Jamieson CH, Ailles LE, Dylla SJ. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med. 2004; 351(7):657-667.","DOI":"10.1056\/NEJMoa040258"},{"key":"48429","doi-asserted-by":"crossref","unstructured":"Christiansson L, Soderlund S, Svensson E. Increased level of myeloid-derived suppressor cells, programmed death receptor ligand 1\/programmed death receptor 1, and soluble CD25 in Sokal high risk chronic myeloid leukemia. PLoS One. 2013; 8(1):e55818.","DOI":"10.1371\/journal.pone.0055818"},{"key":"48430","doi-asserted-by":"crossref","unstructured":"Christiansson L, Soderlund S, Mangsbo S. The tyrosine kinase inhibitors imatinib and dasatinib reduce myeloid suppressor cells and release effector lymphocyte responses. Mol Cancer Ther. 2015; 14(5):1181-1191.","DOI":"10.1158\/1535-7163.MCT-14-0849"},{"key":"48431","doi-asserted-by":"crossref","unstructured":"Hughes A, Clarson J, Tang C. CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors. Blood. 2017; 129(9):1166-1176.","DOI":"10.1182\/blood-2016-10-745992"},{"key":"48432","doi-asserted-by":"crossref","unstructured":"Mumprecht S, Schurch C, Schwaller J, Solenthaler M, Ochsenbein AF. Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T-cell exhaustion and disease progression. Blood. 2009; 114(8):1528-1536.","DOI":"10.1182\/blood-2008-09-179697"},{"key":"48433","doi-asserted-by":"crossref","unstructured":"Hughes A, Yong ASM. Immune effector recovery in chronic myeloid leukemia and treatment-free remission. Front Immunol. 2017; 8:469.","DOI":"10.3389\/fimmu.2017.00469"},{"key":"48434","doi-asserted-by":"crossref","unstructured":"Hsieh YC, Kirschner K, Copland M. Improving outcomes in chronic myeloid leukemia through harnessing the immunological landscape. Leukemia. 2021; 35(5):1229-1242.","DOI":"10.1038\/s41375-021-01238-w"},{"key":"48435","doi-asserted-by":"crossref","unstructured":"Carlsten M, J\u00e4r\u00e5s M. Natural killer cells in myeloid malignancies: immune surveillance, NK cell dysfunction, and pharmacological opportunities to bolster the endogenous NK cells. Front Immunol. 2019; 10:2357.","DOI":"10.3389\/fimmu.2019.02357"},{"key":"48436","doi-asserted-by":"crossref","unstructured":"Giallongo C, Parrinello N, Brundo MV. Myeloid derived suppressor cells in chronic myeloid leukemia. Front Oncol. 2015; 5:107.","DOI":"10.3389\/fonc.2015.00107"},{"key":"48437","doi-asserted-by":"crossref","unstructured":"Bizymi N, Bjelica S, Kittang AO. Myeloid-derived suppressor cells in hematologic diseases: promising biomarkers and treatment targets. Hemasphere. 2019; 3(1):e168.","DOI":"10.1097\/HS9.0000000000000168"},{"key":"48438","doi-asserted-by":"crossref","unstructured":"Norde WJ, Maas F, Hobo W. PD-1\/PD-L1 interactions contribute to functional T-cell impairment in patients who relapse with cancer after allogeneic stem cell transplantation. Cancer Res. 2011; 71(15):5111-5122.","DOI":"10.1158\/0008-5472.CAN-11-0108"},{"key":"48439","doi-asserted-by":"crossref","unstructured":"Giallongo C, Parrinello N, Tibullo D. Myeloid derived suppressor cells (MDSCs) are increased and exert immunosuppressive activity together with polymorphonuclear leukocytes (PMNs) in chronic myeloid leukemia patients. PLoS One. 2014; 9(7):e101848.","DOI":"10.1371\/journal.pone.0101848"},{"key":"48440","doi-asserted-by":"crossref","unstructured":"Chen CI, Koschmieder S, Kerstiens L. NK cells are dysfunctional in human chronic myelogenous leukemia before and on imatinib treatment and in BCR-ABL-positive mice. Leukemia. 2012; 26(3):465-474.","DOI":"10.1038\/leu.2011.239"},{"key":"48441","doi-asserted-by":"crossref","unstructured":"Irani YD, Hughes A, Clarson J. Successful treatment-free remission in chronic myeloid leukaemia and its association with reduced immune suppressors and increased natural killer cells. Br J Haematol. 2020; 191(3):433-441.","DOI":"10.1111\/bjh.16718"},{"key":"48442","doi-asserted-by":"crossref","unstructured":"Ilander M, Olsson-Stromberg U, Schlums H. Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia. Leukemia. 2017; 31(5):1108-1116.","DOI":"10.1038\/leu.2016.360"},{"key":"48443","doi-asserted-by":"crossref","unstructured":"Rea D, Henry G, Khaznadar Z. Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study. Haematologica. 2017; 102(8):1368-1377.","DOI":"10.3324\/haematol.2017.165001"},{"key":"48444","doi-asserted-by":"crossref","unstructured":"Arora R, Press RD. Measurement of BCR-ABL1 transcripts on the International Scale in the United States: current status and best practices. Leuk Lymphoma. 2017; 58(1):8-16.","DOI":"10.1080\/10428194.2016.1190974"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2022.281878\/75321","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2022.281878\/75656","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/10965\/75321","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:03:27Z","timestamp":1794045807000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2022.281878"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,2]]},"references-count":45,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,6,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2022.281878","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2,2]]}}}